Table 3.

IC₅₀ of selected agents

Cancer type	Cell line	Drug	Average IC50 (nM)
PTC	K2	Docetaxel	2.12 ± 0.54
		LBH-589	0.79 ± 0.54
		Pralatrexate	n/aa
ATC	U-Hth83	Docetaxel	1.02 ± 0.26
		LBH-589	0.06 ± 0.01
		Pralatrexate	1.35 ± 0.11

To determine the IC₅₀ of each agent, docetaxel, LBH-589, or pralatrexate were added to cells for 72 h at varying concentrations (6 replicates). Concentrations were selected based on the initial high throughput screening assay. After drug treatment, MTT (Thiazoyl Blue Tetrazolium Bromide) was added to stain cells followed by dimethylsulfoxide and absorption at 570 nm was measured using a SPECTROstar or CLARIOstar plate reader. IC₅₀ was determined using Prism 8.0 software. Average IC₅₀ was determined from 3 independent assays.

^a not available: the IC₅₀ was beyond the range of the cell proliferation assays (10 μM).